Xylem reported revenue for Q1 2025 of $2,069 million, an increase of 1.8% compared to $2,033 million in the prior year. Organic growth was 3.3%. Foreign currency translation had an unfavorable impact on revenue of $26 million.

1. 01

   Xylem reported revenue for Q1 2025 of $2,069 million, an increase of 1.8% compared to $2,033 million in the prior year. Organic growth was 3.3%. Foreign currency translation had an unfavorable impact on revenue of $26 million.

2. 02

   The company said operating income for Q1 2025 was $231 million (operating margin of 11.2%), an increase of $22 million compared to $209 million (10.3%) in the prior year. Adjusted operating income was $325 million (adjusted operating margin of 15.7%).

3. 03

   Xylem said operating cash flow for the 3 months ended March 31, 2025 was $33 million, a decrease compared to $89 million in the prior year. The company cited increased cash used for accounts payable and an increase in accounts receivable as factors in the decline.

4. 04

   The company said total backlog as of March 31, 2025 was $5,095 million, a decrease of 3.4% compared to $5,272 million as of March 31, 2024. Compared to $5,070 million as of December 31, 2024, backlog increased $25 million (0.5%).

Key figures

Quarter ended March 31, 2025

Revenue

$2.1B

Operating income

$231M

Net income

$169M

EPS

$0.69

Gross profit

$768M

Operating cash flow

$33M

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.